Citius Oncology (CTOR) Debt Ratio (2021 - 2022)

Citius Oncology (CTOR) recorded quarterly Debt Ratio of 0.75 in Q3 2022, down 27.22% quarter-over-quarter from 1.03 in Q4 2021.

Citius Oncology (CTOR) Debt Ratio (2021 - 2022) Analysis & Trends

Citius Oncology's Debt Ratio history runs 2 years deep, the most recent figure standing at 0.75 for Q3 2022.

In Q3 2022, Debt Ratio changed N/A year-over-year to 0.75; the TTM figure through Sep 2022 stood at 0.75 (changed N/A YoY), while the FY2021 annual figure was 1.03, changed N/A from the prior year.
Debt Ratio was 0.75 for Q3 2022 at Citius Oncology, down from 1.03 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 1.03 in Q4 2021 to a low of 0.75 in Q3 2022.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Teva Pharmaceutical Industries	38.34 Bn	34.60 Bn	1.97 Bn	0.42
2	Zoetis	33.27 Bn	31.33 Bn	1.62 Bn	0.60
3	United Therapeutics	23.75 Bn	21.60 Bn	648.10 Mn	-
4	Aurora Cannabis	17.11 Bn	17.03 Bn	33.43 Mn	0.01
5	Neurocrine Biosciences	16.37 Bn	15.05 Bn	800.70 Mn	-
6	Elanco Animal Health	11.78 Bn	11.35 Bn	785.00 Mn	0.30
7	Alkermes	7.05 Bn	6.54 Bn	-116.06 Mn	0.35
8	Lantheus Holdings	6.49 Bn	5.99 Bn	230.92 Mn	0.24
9	Hims & Hers Health	6.19 Bn	5.44 Bn	396.79 Mn	-
10	Citius Oncology	75.12 Mn	72.49 Mn	1.34 Mn	-

Historic Data

Download Data

Date	Value
Sep 30, 2022	0.75
Dec 31, 2021	1.03